MyFinsight
Home
Blog
About
Contact
Download
Download image
Product revenues, net
$12,001.3M
(8.90%↑ Y/Y)
Interest income
$490.9M
(-17.92%↓ Y/Y)
Income (loss)
$3,953.2M
(838.09%↑ Y/Y)
Stock-based compensation
expense
$685.9M
(-1.80%↓ Y/Y)
Intangible asset
impairment charges
$379M
Depreciation and
amortization expense
$209.8M
(1.25%↑ Y/Y)
Other liabilities
$148.5M
(274.06%↑ Y/Y)
Other non-cash items,
net
-$113.4M
(-301.42%↓ Y/Y)
Accounts payable
$36.8M
(-25.66%↓ Y/Y)
Canceled cashflow
$8,539M
Net cash provided by
(used in) operating...
$3,631.4M
(837.19%↑ Y/Y)
Effect of changes in
exchange rates on cash
$90.9M
(313.38%↑ Y/Y)
Canceled cashflow
$1,895.2M
Development expenses
$3,081.6M
(9.05%↑ Y/Y)
Selling and other
commercial expenses
$1,102.8M
(31.52%↑ Y/Y)
Cost of
sales-Royalty
$1,049.8M
(3.51%↑ Y/Y)
Research expenses
$827.9M
(2.91%↑ Y/Y)
Provision for income taxes
$690M
(-12.00%↓ Y/Y)
General and
administrative expenses
$650.3M
(3.91%↑ Y/Y)
Cost of
sales-Product
$601.5M
(16.50%↑ Y/Y)
Intangible asset
impairment charge
$379M
Acquired in-process
research and development...
$133M
(-97.13%↓ Y/Y)
Other segment items
$23.1M
(-80.12%↓ Y/Y)
Net increase
(decrease) in cash, cash...
$515.6M
(108.89%↑ Y/Y)
Canceled cashflow
$3,206.7M
Inventories
$524.2M
(1.33%↑ Y/Y)
Deferred income taxes
-$510.8M
(-46.44%↓ Y/Y)
Prepaid expenses and
other assets
$396M
(97.70%↑ Y/Y)
Accounts receivable, net
$347.3M
(249.75%↑ Y/Y)
Accrued expenses
-$116.9M
(-154.91%↓ Y/Y)
Issuances of common stock
under benefit plans
$127.7M
(11.43%↑ Y/Y)
Other financing
activities
$3.7M
(-40.32%↓ Y/Y)
Sales and maturities
of...
$5,897.4M
(32.06%↑ Y/Y)
Proceeds related to
equity securities
$16M
Net cash used in
financing activities
-$2,261.3M
(-51.27%↓ Y/Y)
Net cash used in
investing activities
-$945.4M
(74.92%↑ Y/Y)
Canceled cashflow
$131.4M
Canceled cashflow
$5,913.4M
Repurchases of common stock
$2,017.4M
(71.39%↑ Y/Y)
Payments in connection
with common stock...
$369.9M
(-8.67%↓ Y/Y)
Purchases of
available-for-sale debt securities
$6,396.5M
(-14.00%↓ Y/Y)
Payments on finance
leases
$5.4M
(-83.93%↓ Y/Y)
Purchases of property and
equipment
$437.6M
(46.99%↑ Y/Y)
Other investing
activities
$24.7M
(-54.26%↓ Y/Y)
Back
Back
Cash Flow
source: myfinsight.com
logo-vertex-inc-svg copy-svg
VERTEX PHARMACEUTICALS INC MA (VRTX)
logo-vertex-inc-svg copy-svg
VERTEX PHARMACEUTICALS INC MA (VRTX)